Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Novo Nordisk A/S (NVO)

Novo Nordisk A/S (NVO)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 135,070,784
  • Shares Outstanding, K 2,368,001
  • Annual Sales, $ 17,099 M
  • Annual Income, $ 5,906 M
  • 60-Month Beta 0.61
  • Price/Sales 7.62
  • Price/Cash Flow 20.74
  • Price/Book 17.37

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 7 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/19
See More
  • Average Estimate 0.56
  • Number of Estimates 2
  • High Estimate 0.56
  • Low Estimate 0.55
  • Prior Year 0.54
  • Growth Rate Est. (year over year) +3.70%

Price Performance

See More
Period Period Low Period High Performance
1-Month
52.38 +4.16%
on 10/21/19
58.01 -5.95%
on 11/14/19
+2.04 (+3.88%)
since 10/18/19
3-Month
48.60 +12.26%
on 09/10/19
58.01 -5.95%
on 11/14/19
+3.28 (+6.40%)
since 08/20/19
52-Week
43.60 +25.14%
on 12/26/18
58.01 -5.95%
on 11/14/19
+10.92 (+25.02%)
since 11/20/18

Most Recent Stories

More News
Novo Nordisk expects to meet its current long-term financial targets and introduces strategic aspirations at the Capital Markets Day 2019

Bagsvaerd, Denmark, 20 November 2019 - Novo Nordisk is today hosting a Capital Markets Day where the company is introducing its strategic aspirations.

NVO : 54.36 (-4.70%)
Novo Nordisk Inks Deal With Dicerna to Develop RNAi Therapies

Novo Nordisk (NVO) inks deal with Dicerna Pharmaceuticals to discover and develop novel therapies for the treatment of liver-related cardio-metabolic diseases.

GSK : 43.91 (-1.33%)
NVO : 54.36 (-4.70%)
BMY : 55.75 (-1.29%)
MRK : 84.63 (-0.02%)
New "Cities Changing Diabetes" public-private partnership in Philadelphia mobilizing against city's diabetes epidemic

More than 100 health, faith, business and community leaders from across Philadelphia gathered today to learn about emerging research that identify general characteristics of neighborhoods that may make...

NVO : 54.36 (-4.70%)
Here's Why AstraZeneca's (AZN) Shares Are Up Year to Date

AstraZeneca's (AZN) stock is on an upward trajectory this year. Let us take a look at the reasons for the same.

MRK : 84.63 (-0.02%)
NVO : 54.36 (-4.70%)
GSK : 43.91 (-1.33%)
AZN : 47.14 (-1.11%)
Dicerna and Novo Nordisk Enter Agreement to Discover and Develop RNAi Therapies for Liver-Related Cardio-Metabolic Diseases

--- Each Company to Retain Rights to Co-Develop and

NVO : 54.36 (-4.70%)
DRNA : 23.15 (-3.54%)
AstraZeneca/Merck's Selumetinib NDA Gets FDA Priority Status

The FDA grants priority review to AstraZeneca (AZN) and Merck's NDA for MEK 1/2 inhibitor, selumetinib. Additionally, Qtrilmet tablets to treat type-II diabetes get approval in the EU.

MRK : 84.63 (-0.02%)
AZN : 47.14 (-1.11%)
NVO : 54.36 (-4.70%)
GSK : 43.91 (-1.33%)
4 Big Drugmakers to Bet on After a Great Earnings Season

Big drugmakers post better-than-expected Q3 results, leading to rise in share price of most of the companies in the industry.

ABBV : 87.53 (-1.67%)
PFE : 37.22 (-1.17%)
NVO : 54.36 (-4.70%)
BMY : 55.75 (-1.29%)
MRK : 84.63 (-0.02%)
GSK : 43.91 (-1.33%)
JNJ : 135.40 (+0.43%)
The Zacks Analyst Blog Highlights: Microsoft, Novartis, Novo Nordisk, Tesla and General Dynamics

The Zacks Analyst Blog Highlights: Microsoft, Novartis, Novo Nordisk, Tesla and General Dynamics

NVO : 54.36 (-4.70%)
NVS : 90.59 (+0.21%)
GD : 184.84 (-0.06%)
TSLA : 354.87 (-1.29%)
MSFT : 150.04 (-0.23%)
FDA Panel Votes Against Lilly's Jardiance for Type I Diabetes

Eli Lilly (LLY) gets an unfavorable FDA panel vote to expand the label of its type II diabetes medicine Jardiance (2.5 mg) for type I diabetes.

MRK : 84.63 (-0.02%)
NVO : 54.36 (-4.70%)
LLY : 114.56 (-0.47%)
JNJ : 135.40 (+0.43%)
OZEMPIC® is now listed on the Quebec provincial formulary for adults living with type 2 diabetes

Novo Nordisk is pleased to announce Ozempic(®) (semaglutide injection) is now publicly listed in the province of Quebec under the Régie de L'assurance Maladie du Québec (RAMQ). Ozempic(®) is a once-weekly...

NVO : 54.36 (-4.70%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 80% Buy with a Strengthening short term outlook on maintaining the current direction.

Longer term, the trend strength is Strong. Long term indicators fully support a continuation of the trend.

See More Share

Trade NVO with:

Business Summary

Novo Nordisk is a world leader in insulin and diabetes care and also manufactures and markets a variety of other pharmaceutical products. Furthermore the company is the world's largest producer of industrial enzyme products. The company believes that everyone must care for the environment and our natural...

See More

Key Turning Points

2nd Resistance Point 57.63
1st Resistance Point 57.33
Last Price 54.36
1st Support Level 56.79
2nd Support Level 56.55

See More

52-Week High 58.01
Last Price 54.36
Fibonacci 61.8% 52.51
Fibonacci 50% 50.81
Fibonacci 38.2% 49.10
52-Week Low 43.60

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar